This Startup Is Developing Finger-Prick Blood Tests, But Don't Call It Theranos 2

Daniel Levner, co-founder of Israeli startup Sight Diagnostics, is accustomed to fielding questions about Theranos, the Silicon Valley diagnostics company that flamed out after its much-hyped finger-prick blood tests turned out not to work. Sight is developing a variety of diagnostic tools, including a rapid complete blood count (CBC) finger-prick test that’s launching in Europe this week and is in clinical trials in the U.S. The company’s founders raised $30 million in two rounds of financing and are currently out looking for a Series C—and answering a lot of those pesky questions about Theranos.